- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Patent holdings for IPC class A61P 9/10
Total number of patents in this class: 9160
10-year publication summary
|
282
|
271
|
378
|
536
|
477
|
558
|
607
|
518
|
512
|
376
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Daiichi Sankyo Company, Limited | 1884 |
127 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3364 |
72 |
| The Regents of the University of California | 20059 |
71 |
| Osaka University | 3383 |
62 |
| Shionogi & Co., Ltd. | 849 |
58 |
| Novartis AG | 10730 |
54 |
| Takeda Pharmaceutical Company Limited | 2705 |
54 |
| Sunshine Lake Pharma Co., Ltd. | 599 |
49 |
| Bristol-myers Squibb Company | 4867 |
48 |
| Amarin Pharmaceuticals Ireland Limited | 271 |
45 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 833 |
42 |
| Bayer Pharma AG | 1054 |
39 |
| Mitsubishi Tanabe Pharma Corporation | 581 |
39 |
| AstraZeneca AB | 2908 |
37 |
| Kowa Company, Ltd. | 1198 |
35 |
| Centre National de La Recherche Scientifique | 10516 |
32 |
| Astellas Pharma Inc. | 1083 |
32 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 2886 |
32 |
| Amgen Inc. | 4106 |
31 |
| The Johns Hopkins University | 5709 |
31 |
| Other owners | 8170 |